Disseminated Herpes Infection Following Talimogene Laherparepvec Administration
JAMA Dermatol
.
2022 Apr 1;158(4):456-457.
doi: 10.1001/jamadermatol.2022.0020.
Authors
Brooks David Kimmis
1
,
Yen Luu
2
,
Hongyan Dai
3
Affiliations
1
Division of Dermatology, University of Kansas Hospital, Kansas City.
2
University of Missouri-Kansas City School of Medicine, Kansas City.
3
Department of Pathology and Laboratory Medicine, University of Kansas Hospital, Kansas City.
PMID:
35234818
DOI:
10.1001/jamadermatol.2022.0020
No abstract available
MeSH terms
Biological Products* / adverse effects
Herpesvirus 1, Human*
Humans
Melanoma* / therapy
Oncolytic Virotherapy*
Skin Neoplasms* / therapy
Substances
Biological Products
talimogene laherparepvec